GI Pancreatic - Metastatic

Localized

- NeoAdjuvant
  - IRB#11256
    - OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

Adjuvant

- IRB#17751
  - IRB#15304
    - Stand up to Cancer: Study of the Safety, Immunopharmacodynamics and Antitumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#15588
  - IRB#16609
    - AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#17094
  - A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

http://www.ohsu.edu/research/rda/so/knight.php

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

03.26.2018